---
title: "eXoZymes wins USD 2.03 million NIH grant for cannabinoid analog development"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290947188.md"
description: "Exozymes Inc. has secured a $2.03 million NIH NIGMS Phase IIB SBIR grant to advance the development of rare cannabinoids and engineered cannabinoid analogs for drug discovery. The project, starting July 1, 2026, focuses on scaling enzyme systems and conducting preclinical receptor-binding assays. Occidental College will receive a sub-award under this program."
datetime: "2026-06-26T10:03:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290947188.md)
  - [en](https://longbridge.com/en/news/290947188.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290947188.md)
generator: "portal-rs"
---

# eXoZymes wins USD 2.03 million NIH grant for cannabinoid analog development

-   Exozymes secured a $2.03 million NIH NIGMS Phase IIB SBIR grant to advance rare cannabinoids and engineered cannabinoid analogs for drug discovery. \* Work is slated to start July 1, 2026, targeting scale-up of enzyme systems and preclinical receptor-binding assays for its cannabinoid library. \* Occidental College, via Vikram Shende’s lab, will receive a sub-award under the program. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-030205), on June 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [EXOZ.US](https://longbridge.com/en/quote/EXOZ.US.md)

## Related News & Research

- [Exozymes wins NIH grant worth $2.03 million for cannabinoid analog development](https://longbridge.com/en/news/290734082.md)
- [This dime could sell for more than $1 million: How to tell if yours is worth the same](https://longbridge.com/en/news/297433489.md)
- [Conyers Investments reports disposal of 13,350 Newsmax class B shares worth $147,325.16](https://longbridge.com/en/news/297554233.md)
- [14:52 ETAPhA Foundation Announces 2026 Pinnacle Award Recipients](https://longbridge.com/en/news/297361032.md)
- [Veeva President and Chief Customer Officer Thomas D. Schwenger sells 10,000 shares for $2.81 million](https://longbridge.com/en/news/297559990.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**